bacterial meningitis in adults: host and pathogen … · nationwide studies of adults with...
TRANSCRIPT
UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome
Heckenberg, S.G.B.
Link to publication
Citation for published version (APA):Heckenberg, S. G. B. (2013). Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome
General rightsIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, statingyour reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Askthe Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,The Netherlands. You will be contacted as soon as possible.
Download date: 16 Sep 2018
Chapter 1
8
Bacterial meningitis occurs when bacteria invade the subarachnoid space
surrounding the brain and spinal cord. This infection and the ensuing
inflammatory response cause severe, life-threatening disease. Until the
advent of antibacterial agents effective treatment was lacking. After initial
success using intrathecal meningococcal antiserum in the first decades of the
twentieth century, the introduction of sulfonamides in the 1930s provided the
first effective antibiotic therapy for bacterial meningitis caused by Haemophilus
influenzae type B and Neisseria meningitidis. Subsequently, penicillin treatment
for pneumococcal meningitis was implemented in the 1940s. In meningococcal
disease, increasing resistance to sulfonamides prompted its replacement by
penicillin. 1, 2
Epidemiology
To monitor the epidemiology of bacterial meningitis, the Netherlands Reference
Laboratory for Bacterial Meningitis was officially established in 1975 and
isolates from cerebrospinal fluid (CSF) from patients with bacterial meningitis
have been stored and collected. The implementation of conjugate vaccination
against type B H. influenzae, group C N. meningitidis, and most recently, the
pneumococcal vaccine have reduced the incidence of bacterial meningitis
in the Netherlands. Currently, approximately 85% percent of all bacterial
meningitis is caused by N. meningitidis and Streptococcus pneumoniae. Other
causes are Listeria monocytogenes, H. influenzae and Streptococcus agalactiae.3
N. meningitidis (the meningococcus) is a common inhabitant of the human
nasopharynx. Carriage is found exclusively in humans. Disease occurs when
meningococci invade the mucosal space and enter the bloodstream. Invasive
disease can progress swiftly and fatally, mainly through sepsis and meningitis.
The incidence of meningococcal meningitis in adults in the Netherlands is
approximately 1 per 100,000. In the Netherlands, the most common serogroups
are B and C, while serogoup A is the cause of severe epidemics in the “meningitis-
belt” in sub-Saharan Africa. Since the implementation of vaccination with the
MenC vaccine, the incidence of group C disease has decreased substantially in
the Netherlands. In 1998, a new method of typing meningococci was described
using nucleotide sequencing of meningococcal genes. Multilocus sequence
typing (MLST) has provided a useful tool for the unambiguous characterisation
24407 Heckenberg.indd 8 25-02-13 11:11
IntroductIon
9
Ch
apt
er 1of meningococci and allows for rapid identification of invasive lineages of
meningococci.4
S. pneumoniae (the pneumococcus) is a major cause of respiratory infections,
sepsis and meningitis worldwide. In pneumococcal meningitis, mortality
remains high (20-30%) despite effective antiobiotic treatment. Over 90
serotypes have been described. Increasing antibiotic resistence is an emerging
challenge worldwide with rates of resistance exceeding 50% in parts of the
United States. However, antibiotic resistance in the Netherlands remains low. In
2006, the heptavalent pneumococcal vaccine was implemented in the national
vaccination program in the Netherlands.
Treatment and outcome
Although the prognosis of patients with bacterial meningitis has improved
greatly through effective antibiotic treatment, substantial morbidity and
mortality has remained, fuelling research into adjunctive treatment. Following
experimental animal studies, attenuation of the severe inflammatory
response emerged as an important pathway for improving clinical outcome.
Since the 1960s, clinical trials with adjunctive corticosteroid treatment have
been performed with conflicting results. However, meta-analyses showed a
reduction in hearing loss in patients treated with adjunctive corticosteroids.5
In 2002, a European randomized clinical trial showed beneficial effect of
adjunctive dexamethasone in adults with bacterial meningitis. The effect was
most pronounced in pneumococcal meningitis and mortality in those patients
was reduced by 10%. However, these results were not reproduced in clinical
trials from other parts of the world. An individual patient data-analysis and
subsequent Cochrane review supported the continued use of dexamethasone
in children and adults in high-income countries. 6-8
Adequate antibiotic and adjunctive therapy in combination with supportive
care have reduced the mortality of bacterial meningitis, but neurologic
sequelae in patients surviving bacterial meningitis are common, particularly
in pneumococcal meningitis. They include cognitive impairment, hearing loss,
epilepsy and other focal neurological deficits. 9-11
24407 Heckenberg.indd 9 25-02-13 11:11
Chapter 1
10
Aims and outline of this thesis
In chapter 2 we present the results of a nationwide study in adults with
meningococcal meningitis. Details of clinical characteristics, therapy and
outcome are presented, as well as the correlation of bacterial genotype,
acquired through MLST analysis, and clinical characteristics. Chapter 3
describes the collaborative effort of our research group with the Netherlands
Vaccine Institute. The discovery of meningococci with an impaired potential
to induce cytokine production is described. Furthermore, the mutations in
bacterial genome are revealed and the relationship with clinical characteristics
in patients from our nationwide cohort studies is investigated. In chapters 4
and 5, we present the results of nationwide studies from 2006-2009 on the
implementation of dexamethasone treatment in the Netherlands. Outcome in
patients was compared to a cohort of 1998-2002, before the implementation
of dexamethasone. The influence of dexamethasone treatment on outcome in
meningococcal meningitis is described in chapter 4. Chapter 5 describes the
change in outcome in adults wih pneumococcal meningitis and we compare
the observed outcome with that in a prognostic model. Chapter 6 describes the
incidence of hearing loss following pneumococcal meningitis, combining two
nationwide studies of adults with bacterial meningitis, from 1998-2002 and from
2006-2009. The association between clinical characteristics, pneumococcal
serotype and occurrence of hearing loss is described. In Chapter 7 the results
of our cooperation with a research group in Munich, Germany are presented.
We describe the association of unfavorable outcome with a single nucleotide
polymorphism (SNP) coding for complement factor C5. Next, C5 fragment
levels in CSF and the relationship with clinical characteristics were investigated.
Finally, a mouse model of C5a deficient mice and adjuvant treatment with
C5-specific monoclonal antibodies are described. In chapter 8, we conclude
with a general discussion describing the epidemiology, pathophysiology and
treatment of bacterial meningitis incorporating the results of the presented
studies and suggestions for future research are proposed.
24407 Heckenberg.indd 10 25-02-13 11:11
IntroductIon
11
Ch
apt
er 1References
1. Uiterwijk A, Koehler PJ. A history of acute bacterial meningitis. J Hist Neurosci 2012;21(3):293-313.
2. Swartz MN. Bacterial meningitis - a view of the past 90 years. N Engl J Med 2004;351(18):1826-1828.
3. Tunkel AR. Bacterial Meningitis. Philadelphia: Lippincott, Williams & Wilkins; 2001.
4. Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998;95(6):3140-3145.
5. McIntyre PB, Berkey CS, King SM et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997;278(11):925-931.
6. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010;9:CD004405.
7. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347(20):1549-1556.
8. van de Beek D, Farrar JJ, de Gans J et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010;9(3):254-263.
9. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol 2006;5(2):123-129.
10. Ostergaard C, Konradsen HB, Samuelsson S. Clinical presentation and prognostic factors of Streptococcus pneumoniae meningitis according to the focus of infection. BMC Infect Dis 2005;5:93.
11. Zoons E, Weisfelt M, de Gans J et al. Seizures in adults with bacterial meningitis. Neurology 2008;70(22 Pt 2):2109-2115.
24407 Heckenberg.indd 11 25-02-13 11:11